News Website

New AI femtech competition in Portugal aims to fast-track women’s health innovation - Tech.eu

New AI femtech competition in Portugal aims to fast-track women’s health innovation Tech.eu

Published: April 10, 2026, 8:35 a.m.

Read Full Article

New NHS pathways aims to speed up endometriosis diagnosis and treatment - FemTech World

New NHS pathways aims to speed up endometriosis diagnosis and treatment FemTech World

Published: April 9, 2026, 8:06 a.m.

Read Full Article

Proseek Bio raises AU$1.5m for ovarian cancer blood test - FemTech World

Proseek Bio raises AU$1.5m for ovarian cancer blood test FemTech World

Published: April 8, 2026, 11 a.m.

Read Full Article

Proseek Bio raises AU$1.5m for ovarian cancer blood test - femtechworld.co.uk

Proseek Bio raises AU$1.5m for ovarian cancer blood test femtechworld.co.uk

Published: April 8, 2026, 11 a.m.

Read Full Article

NICE issues fertility guidance for people with endometriosis - FemTech World

NICE issues fertility guidance for people with endometriosis FemTech World

Published: April 7, 2026, 11:05 a.m.

Read Full Article

CSF3R signalling beyond granulopoiesis: new paradigms in female reproductive biology.

The Colony-Stimulating Factor 3 Receptor (CSF3R), the receptor for granulocyte colony-stimulating factor (G-CSF), has expanded from a hematopoietic regulator to a multifunctional signalling molecule with significant relevance in gynaecological biology. …

Published: April 7, 2026, midnight

Read Full Article

CSF3R signalling G-CSF JAK-STAT pathway MAPK/ERK pathway Reproductive biology

Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment - Femtech Insider

Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment Femtech Insider

Published: April 1, 2026, 11:54 a.m.

Read Full Article

Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment - femtechinsider.com

Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment femtechinsider.com

Published: April 1, 2026, 11:54 a.m.

Read Full Article

Report reveals what women’s health innovators get wrong about coverage - FemTech World

Report reveals what women’s health innovators get wrong about coverage FemTech World

Published: March 31, 2026, 11 a.m.

Read Full Article

[Angelica sinensis polysaccharide ameliorates endometriosis in rats by restoring autophagic homeostasis via inhibition of Keap1/Nrf2/HO-1-mediated oxidative stress].

To investigate whether Angelica sinensis polysaccharide (ASP) ameliorates endometriosis (EMT) by suppressing oxidative stress and restoring autophagy via the Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2)/heme …

Published: March 31, 2026, midnight

Read Full Article

Angelica sinensis polysaccharide Autophagy Endometriosis Keap1/Nrf2/HO-1 pathway Oxidative stress SD rats

Latest Articles

New AI femtech competition in Portugal aims to fast-track women’s health innovation - Tech.eu

New NHS pathways aims to speed up endometriosis diagnosis and treatment - FemTech World

Proseek Bio raises AU$1.5m for ovarian cancer blood test - FemTech World

Proseek Bio raises AU$1.5m for ovarian cancer blood test - femtechworld.co.uk

NICE issues fertility guidance for people with endometriosis - FemTech World

CSF3R signalling beyond granulopoiesis: new paradigms in female reproductive biology.

Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment - Femtech Insider

Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment - femtechinsider.com

Report reveals what women’s health innovators get wrong about coverage - FemTech World

[Angelica sinensis polysaccharide ameliorates endometriosis in rats by restoring autophagic homeostasis via inhibition of Keap1/Nrf2/HO-1-mediated oxidative stress].

Subscribe to Our Newsletter